Short Business Description:

Clee Medical is transforming brain surgery with an advanced platform that combines ultra-high-resolution real-time imaging, AI-based navigation, and machine learning. This technology allows surgeons to operate with extreme precision, reducing risks and improving patient outcomes. By offering better visualization of complex brain structures, it enables safer, more effective treatments for neurological conditions. The system also lowers healthcare costs, speeds up recovery, and expands access to life-saving therapies.

Clee Medical SA is transforming the field of brain surgery by redefining how neurosurgeons visualize, navigate, and access the most delicate regions of the human brain. Headquartered in Geneva, the company is developing a next-generation surgical platform that integrates ultra-high-resolution real-time imaging with AI-based navigation and machine learning tools. This breakthrough technology empowers surgical teams to operate with unmatched accuracy, significantly reducing complications and pushing the boundaries of what is possible in minimally invasive brain interventions.

For millions suffering from neurological disorders – ranging from Parkinson’s disease to brain tumors – treatment options are limited by today’s surgical tools, which lack the resolution and precision to safely reach targeted areas of the brain. Clee Medical’s platform offers imaging with 125,000 times more voxels per unit volume than current systems, giving clinicians a far clearer view of neuroanatomy and vasculature during surgery. Combined with intelligent navigation and machine learning detection, the system enables more precise electrode placement, safer biopsies, and faster recovery for patients.

The impact is profound: by enhancing surgical accuracy, Clee Medical not only improves patient outcomes but also reduces healthcare costs and widens access to advanced neurotherapies. Their approach combines capital equipment with single-use disposables, creating a scalable, high-impact business model for hospitals and surgical centers worldwide. Within five years, their first product is expected to be approved and in use across Switzerland, the EU, and the U.S., with adoption by leading neurosurgical teams and ongoing clinical research unlocking new treatment possibilities.

At the helm is founder and CEO Matthew Lapinski, whose career spans innovation in medical technologies and global market development. His vision for Clee Medical is grounded in both technological ambition and clinical empathy, focusing on the needs of surgeons and patients alike. Under his leadership, the company is assembling a team across Europe and North America to bring this critical innovation to market.